Φορτώνει......
Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells
Galectin 3 (LGALS3) expression is prognostic for poor survival in acute myeloid leukemia (AML) patients. GCS-100 is a novel galectin inhibitor that may prove useful for AML therapy. In this study, we found GCS-100 induced apoptosis in AML cells. The agent reduced MCL-1 expression suggesting GCS-100...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Biochim Biophys Acta |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2015
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4775369/ https://ncbi.nlm.nih.gov/pubmed/26704388 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbamcr.2015.12.008 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|